ClinicalTrials.gg
RecruitingNCT06986148STAMPPUpdated Nov 17, 2026

Comparing Antibiotic Treatment Strategies for Children With Pneumonia in Outpatient Settings: (STAMPP)

An interventional study of Immediate Antibiotic Prescribing Group Instructions and Safety Net Antibiotic Prescribing (SNAP) Group Instructions in Community Acquired Pneumonia (CAP) and Community Acquired Pneumonia, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago. Recruiting at 9 sites in United States. Open to participants aged 12 Months to 71 Months. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Ann & Robert H Lurie Children's Hospital of Chicago · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.
Updated Nov 17, 2026Site recruiting status changedEligibility revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,000
Allocation
Randomized
Ages
12 Months to 71 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Community-Acquired Pneumonia with a site in United States — 9 open to participants now, 12 under way, 3 of them phase 3. Community-Acquired Pneumonia · United States.

Planned enrollment
6th of 42
2,000 · median 190
Started
2025
with 3 others
No phase
12 of 52
1 open now
Primary completion
2029-06
later than 10 of 11 live
Registered
48th of 52
by date
Lead sponsor
3 of 52
Ann & Robert H Lurie Children's Hospital of Chicago

Among the 52 studies in Community-Acquired Pneumonia with a site in United States, this one is the 6th largest by planned enrollment of the 42 interventional ones that give a count, is one of 4 that started in 2025, is one of 12 with no phase, reaches primary completion later than 10 of the 11 other live ones, and was the 48th registered.

Community-Acquired Pneumonia

325 studies on the registry are indexed under Community-Acquired Pneumonia; 77 are open to participants now.

Browse Community-Acquired Pneumonia studies →

Open to participants now

9 of the 52 studies in Community-Acquired Pneumonia with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 41 Community-Acquired Pneumonia studies recruiting now, 29 (71%) set no upper age limit and 9 (22%) stop at 75 or younger; 13 take children under 18; 5 take healthy volunteers.

This study: 12 Months to 71 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Community-Acquired Pneumonia with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to determine if a "watch and wait" antibiotic strategy, called Safety Net Antibiotic Prescribing (SNAP), can safely reduce unnecessary antibiotic use while ensuring that children diagnosed with community-acquired pneumonia get better from their illness. The main aims of this study are:

  • To compare the effectiveness of SNAP versus immediate antibiotic prescribing in children with mild community-acquired pneumonia (CAP)
  • To identify which patient groups benefit most from the SNAP strategy
  • To identify factors that shape implementation of each prescribing strategy.

Researchers will compare the SNAP strategy (where parents or guardians are instructed to give antibiotics only if their child is not improving after 72 hours, or sooner if they are worsening) to the immediate antibiotic prescribing strategy (where parents or guardians are instructed to give the antibiotics right after their healthcare visit) to see if one strategy is more effective than the other.

Participants will be randomly assigned to either the immediate antibiotic group or the SNAP group at enrollment. Participation lasts 14 days with follow-up surveys at 4, 7, and 14 days after enrollment.

Read the detailed description

This study is a multicenter, Hybrid Type-1effectiveness-implementation randomized clinical trial (RCT) designed to evaluate the effectiveness of a "Safety Net Antibiotic Prescribing" (SNAP) strategy versus an immediate antibiotic prescribing strategy for young children 12 months to \<6 years of age with community-acquired pneumonia (CAP) who are treated as outpatients.

This study will recruit eligible patients from approximately 19 clinical sites consisting of pediatric emergency departments (EDs), primary care offices, and urgent care centers within the United States and enroll up to 2,000 patients. Patient recruitment will occur over a 3.5-year period. Participants will be identified and screened during routine visits at the clinical sites.

Through an online system, participants will be randomized to either the immediate antibiotic group or the SNAP group. All participants will receive a prescription for antibiotics as per usual care from their treating clinician.

The parents or guardians of the participants will be asked to complete an online survey on Days 4 and 14 (+/- 2 days) to collect data for the secondary outcomes, including quality of life, satisfaction, and return visits. On Day 7 (+/- 2 days), the parents or guardians of the participants will be contacted by phone to collect data for the primary outcome, focusing on clinical improvement and antibiotic use.

Acceptability and feasibility will be assessed with parent or guardian and clinician surveys and interviews. Parents or guardians will be surveyed at Day 14 and a subset will be invited for interviews within a month of the final follow-up visit. Clinicians will be surveyed, and a subset will be interviewed at the conclusion of the trial.

03

Conditions studied

  • Community Acquired Pneumonia (CAP)
  • Community Acquired Pneumonia

Keywords

  • Community-acquired Pneumonia
  • Pediatric Respiratory Diseases
  • Pneumonia
  • Antibiotic Use
  • SNAP
04

Who can participate

The criteria were revised on the registry on Nov 17, 2026. See what changed

Ages eligible
12 Months to 71 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aims 1 and 2:
  • Presenting with signs and symptoms of lower respiratory tract infection
  • Diagnosed with community-acquired pneumonia (CAP) by a clinician
  • The treating clinician intends to prescribe antibiotics for CAP, AND
  • Well enough, as determined by the clinician at the time of the study enrollment visit, to be managed as an outpatient.
  • Aim 3:
  • Parent/guardian of child enrolled in the trial, OR
  • Clinician who makes prescribing decision at the study site, OR
  • Other practice-based parties (e.g. nurses, pharmacists, medical assistants, practice leaders) at study sites who can comment on the implementation of each prescribing strategy.

Exclusion criteria

Exclusion Criteria:

  • Aims 1 and 2:
  • Hospitalization within the previous 7 days
  • Oxygen saturation below 90%, if measured
  • Incomplete immunization status (e.g., lacking at least 3 doses of the pneumococcal vaccines, typically given as part of the 2-, 4-, and 6-month vaccinations)
  • Chronic medical conditions that increase the risk of bacterial CAP (e.g., chronic lung disease, cystic fibrosis, sickle cell disease),
  • Substantially status (e.g., immunodeficiency, active cancer treatment, organ transplant with concurrent immunosuppressive agents)
  • Receipt of oral or parenteral antibiotics within the previous 7 days
  • Diagnosis of complicated pneumonia (e.g., empyema, lung abscess)
  • Known bacterial source of infection warranting immediate antibiotics
  • Pneumonia diagnosis within the previous 2 months, OR
  • Prior enrollment in the trial
  • Inability of the parent or guardian to speak English or Spanish
  • Aim 3:
  • Inability of the parent or guardian to speak English
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,000 participants (estimated)

Study arms

  • Active comparator
    Immediate Antibiotic Prescribing

    For participants randomized to this arm, a prescription is filled and the antibiotic is administered right after the index visit.

    Other: Immediate Antibiotic Prescribing Group Instructions

  • Other
    Safety Net Antibiotic Prescribing (SNAP)

    For participants randomized to this arm, a prescription is provided, but the patient is instructed not to take the antibiotic unless the child is not improving at 72 hours or sooner if getting worse.

    Other: Safety Net Antibiotic Prescribing (SNAP) Group Instructions

Interventions

  • OtherImmediate Antibiotic Prescribing Group Instructions

    Children randomized to the immediate antibiotic prescribing group will receive an antibiotic prescription with instructions to fill and administer the antibiotics.

  • OtherSafety Net Antibiotic Prescribing (SNAP) Group Instructions

    For children randomized to the SNAP group, their parents or guardians will receive a prescription for antibiotics, but will be told not to administer the antibiotic unless their child's symptoms show no improvement at 72 hours or worsen within 72 hours.

06

What researchers measure

Primary outcomes

  1. Clinical Improvement

    Clinical improvement at 7 days after the index visit, defined as parent-reported (a) perception of overall improvement, (b) no worsening of fever, work of breathing, concerning changes in activity, or decreased oral intake, (c) no new antibiotic use or hospitalization following the index visit, and (d) improvement in at least one key pneumonia symptom in (b).

    Time frame: From enrollment to day 7

  2. Antibiotic Use

    Antibiotic use through 7 days after the index visit, defined as Parent-reported antibiotic use (yes/no) at 7 days.

    Time frame: From enrollment to day 7

Secondary outcomes

  1. Antibiotic Exposure

    Antibiotic exposure, defined as the number of days antibiotics were consumed through day 7 and day 14.

    Time frame: From enrollment to day 14

  2. Clinical Improvement

    Clinical improvement at day 4 and day 14. Clinical improvement is defined as parent-reported perception of overall improvement, no worsening of fever, work of breathing, concerning changes in activity, or decreased oral intake, no new antibiotic use or hospitalization following the index visit, and improvement in at least one of these key pneumonia symptoms. Symptom improvement is assessed on an ordinal scale with "Much Worse" as the minimum measurement and "Much Better" as the maximum measurement.

    Time frame: From enrollment to day 14

  3. Parent Satisfaction

    Parent-reported satisfaction with the treatment strategy at day 14. Parent-reported satisfaction with the treatment strategy is assessed on an ordinal scale with "Very Dissatisfied" as the minimum measurement and "Very Satisfied" as the maximum measurement.

    Time frame: From enrollment to day 14

  4. Quality of Life Measures

    Quality of life, defined by parent/guardian using the Pediatric Quality of Life Inventory (PedsQL) at days 7 and 14

    Time frame: From enrollment to day 14

  5. Return to Care

    Parent-reported return to medical care after index visit and reason for return

    Time frame: From enrollment to day 14

Other outcomes

  1. Antibiotic-associated Adverse Events

    Rash, diarrhea, diaper dermatitis, oral thrush, vomiting, anaphylaxis

    Time frame: From enrollment to day 14

07

Study locations

3 of 9 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — At the conclusion of the study, a de-identified dataset will be prepared and made available for sharing with investigators as specified by the lead investigators and the funding agency. Data sharing will follow established guidelines to ensure that any shared dataset does not contain protected health information (PHI) and is fully anonymized. Investigators requesting access to the dataset will need to submit a data use agreement, specifying how the data will be used. Results of the study will be disseminated through peer-reviewed journals, presentations at scientific meetings, and the PCORI website. Aim 3 interview transcripts will not be shared to a publicly available repository since it will be impossible to fully anonymize the transcripts.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Jun 2029, 45 months after the start.

Of 42 non-industry interventional studies with no phase under Community-Acquired Pneumonia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 38. This study's planned 45 months is above that.

Counting every sponsor, half of 43 studies reached it within 24 months; a quarter within 14 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2025
First posted
May 22, 2025
StartActual
Sep 9, 2025
Primary completionEst.
Jun 30, 2029
CompletionEst.
Jul 16, 2029
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added. Primary Children's Hospital is now Completed
Show 5 added (5 United States)
  • Children's Hospital Los Angeles · Los Angeles, United States
  • Rady Children's Hospital - San Diego · San Diego, United States
  • UCSF Benioff Children's Hospital - San Francisco · San Francisco, United States
  • Children's National Hospital · Washington D.C., United States
  • Children's Mercy · Kansas City, United States
Nov 17, 2026
Eligibility
1 exclusion criterion edited
What changed in the criteria
Exclusion criteria
  • EditedPneumonia diagnosis within the previous 62 months, OR
Nov 17, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Primary Children's Hospital · Salt Lake City, United StatesContact removed t•••@hsc.utah.edu · •••7430Contact removed j•••@hsc.utah.eduContact removed (no phone or email listed)
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    5 sites added. Primary Children's Hospital is now Completed
    Show 5 added (5 United States)
    • Children's Hospital Los Angeles · Los Angeles, United States
    • Rady Children's Hospital - San Diego · San Diego, United States
    • UCSF Benioff Children's Hospital - San Francisco · San Francisco, United States
    • Children's National Hospital · Washington D.C., United States
    • Children's Mercy · Kansas City, United States
    Eligibility 1 exclusion criterion edited
    What changed in the criteria
    Exclusion criteria
    • EditedPneumonia diagnosis within the previous 62 months, OR
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Primary Children's Hospital · Salt Lake City, United StatesContact removed t•••@hsc.utah.edu · •••7430Contact removed j•••@hsc.utah.eduContact removed (no phone or email listed)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06986148
Collaborators
Patient-Centered Outcomes Research Institute
Responsible party
Todd A. Florin (Associate Division Head for Academic Affairs & Research, Division of Emergency Medicine, Ann & Robert H Lurie Children's Hospital of Chicago) — Principal investigator
First posted
May 22, 2025
Start date
Sep 9, 2025
Primary completion
Jun 30, 2029 (estimated)
Completion
Jul 16, 2029 (estimated)
Last update
Nov 17, 2026

Study contacts

Todd Florin, MD, MSCE
Contact
taflorin@luriechildrens.org
312-227-6675
Julia Szymczak, PhD
Contact
julia.szymczak@hsc.utah.edu
Todd Florin, MD, MSCE
principal investigator · Ann & Robert H Lurie Children's Hospital of Chicago
Julia Szymczak, PhD
principal investigator · University of Utah

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion